Vincerx Pharma (VINC) News Today → BUY ALERT: Tiny tech play partners with US government (From Stansberry Research) (Ad) Free VINC Stock Alerts $0.88 -0.05 (-5.39%) (As of 05/3/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 50.0%americanbankingnews.com - April 28 at 5:18 AMWhy Vincerx Pharma (VINC) Stock Is Fallingmsn.com - April 26 at 8:27 PMVincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrantsglobenewswire.com - April 26 at 12:27 AMVincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrantsglobenewswire.com - April 25 at 4:01 PMVincerx Pharma, Inc. Common Stock (VINC)nasdaq.com - April 23 at 2:06 AMAgendia’s BluePrint Included in German Oncology Group Guidelinesfinance.yahoo.com - April 12 at 9:45 AMThe Rise of Zyn: The Oral Nicotine Product Going Viralfinance.yahoo.com - April 10 at 4:08 PMVincerx Pharma Inc (VINC) Gets a Buy from Leerink Partnersmarkets.businessinsider.com - April 10 at 9:44 AMmarketbeat.com - April 9 at 9:36 AMACOR, HUBC and DATS among pre-market losersmsn.com - April 9 at 9:19 AMVincerx in selloff after early-stage data for cancer therapymsn.com - April 9 at 9:19 AMCantor Fitzgerald Reaffirms Overweight Rating for Vincerx Pharma (NASDAQ:VINC)marketbeat.com - April 9 at 8:49 AMWhy Is Vincerx Pharma (VINC) Stock Down 64% Today?investorplace.com - April 9 at 8:40 AMVincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - April 8 at 4:30 PMFY2024 EPS Estimates for Vincerx Pharma, Inc. Raised by Analyst (NASDAQ:VINC)marketbeat.com - April 4 at 9:13 AMQ1 2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Boosted by Leerink Partnrsmarketbeat.com - April 3 at 6:00 AMVINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023investorplace.com - April 2 at 8:06 AMVincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updatefinanznachrichten.de - April 1 at 4:30 PMVincerx Pharma (NASDAQ:VINC) Receives Overweight Rating from Cantor Fitzgeraldmarketbeat.com - April 1 at 12:23 PMVincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024finance.yahoo.com - April 1 at 10:47 AMVincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Lookfinance.yahoo.com - March 29 at 8:49 PMVincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024marketwatch.com - March 29 at 3:48 PMVincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updateglobenewswire.com - March 29 at 3:20 PMShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%marketbeat.com - March 28 at 8:34 AMVincerx Pharma (VINC) Set to Announce Earnings on Tuesdaymarketbeat.com - March 25 at 7:31 AMVincerx Pharma Incedition.cnn.com - March 19 at 11:56 PMWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com - March 12 at 2:55 PMLeerink Partnrs Comments on Vincerx Pharma, Inc.'s Q1 2024 Earnings (NASDAQ:VINC)marketbeat.com - March 9 at 1:39 AMFY2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Reduced by Leerink Partnrsmarketbeat.com - March 8 at 7:20 AMBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug Pipelinemarkets.businessinsider.com - March 7 at 2:29 PMVincerx Pharma, Inc. to Post Q1 2024 Earnings of ($0.40) Per Share, Leerink Partnrs Forecasts (NASDAQ:VINC)marketbeat.com - March 7 at 6:40 AMVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - March 5 at 4:31 PMVincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past weekfinance.yahoo.com - March 5 at 8:12 AMVincerx Pharma Inc Ordinary Shares VINCmorningstar.com - February 22 at 10:08 PMVincerx Pharma Stock (NASDAQ:VINC) Dividends: History, Yield and Datesbenzinga.com - February 22 at 7:06 AMmarketbeat.com - February 21 at 10:14 AMVincerx Pharma stock rises on positive efficacy data from lymphoma therapymsn.com - January 10 at 8:43 AMWhy Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?msn.com - January 8 at 2:14 PMVincerx Pharma Shares Surge Following Early Results for Relapsed, Refractory Lymphomamarketwatch.com - January 8 at 7:53 AMVincerx Pharma, Inc.: Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphomafinanznachrichten.de - January 8 at 2:53 AMVincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphomafinance.yahoo.com - January 7 at 3:31 PMVincerx Pharma GAAP EPS of -$0.46msn.com - November 14 at 4:52 PMVincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 14 at 8:09 AMNew to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Networkfinance.yahoo.com - October 13 at 9:29 AMVincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023finance.yahoo.com - September 19 at 9:09 AMVincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943finance.yahoo.com - September 14 at 7:49 AMDelveInsight Evaluates a Robust B-Cell Lymphoma Clinical Trial as 160+ Influential Pharma Companies to Set Foot in the 7MMbenzinga.com - September 8 at 10:54 PMFDA approves Vincerx’s IND application for trial of VIP943msn.com - August 23 at 6:49 PMCancer Antibody Drug Conjugates Market Size Clinical Trials Insightbenzinga.com - August 23 at 7:28 AMVincerx Pharma receives FDA clearance for early-stage leukemia trialproactiveinvestors.com - August 23 at 2:27 AM Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address The Gold Grab of the Century (Ad)When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago. That's why we have released our Free Precious Metals Investment Guide. VINC Media Mentions By Week VINC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VINC News Sentiment▼0.550.43▲Average Medical News Sentiment VINC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VINC Articles This Week▼11▲VINC Articles Average Week Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RNXT News Today ADXN News Today ONTX News Today APM News Today BIVI News Today INDP News Today TCRT News Today GLTO News Today TXMD News Today LSTA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VINC) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
